After finishing at $0.37 in the prior trading day, Fortress Biotech Inc. (NASDAQ: FBIO) closed at $0.35, down -5.41%. In other words, the price has decreased by -$0.0200 from its previous closing price. On the day, 541416 shares were traded.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
Ratios:
Our goal is to gain a better understanding of FBIO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.00. In the meantime, Its Debt-to-Equity ratio is 3.19 whereas as Long-Term Debt/Eq ratio is at 2.53.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on August 04, 2022, initiated with a Buy rating and assigned the stock a target price of $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 08 when Fortress Biotech, Inc. bought 418,410 shares for $0.72 per share. The transaction valued at 301,255 led to the insider holds 1,032,390 shares of the business.
ROSENWALD LINDSAY A MD bought 10,000 shares of FBIO for $93,400 on Aug 18. The President, CEO & Chairman now owns 112,500 shares after completing the transaction at $9.34 per share. On Aug 17, another insider, ROSENWALD LINDSAY A MD, who serves as the President, CEO & Chairman of the company, bought 10,000 shares for $11.75 each. As a result, the insider paid 117,500 and bolstered with 102,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FBIO now has a Market Capitalization of 46.58M and an Enterprise Value of 49.49M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.78 while its Price-to-Book (P/B) ratio in mrq is 2.06. Its current Enterprise Value per Revenue stands at 0.79 whereas that against EBITDA is -0.25.
Stock Price History:
Over the past 52 weeks, FBIO has reached a high of $1.16, while it has fallen to a 52-week low of $0.31. The 50-Day Moving Average of the stock is 0.4814, while the 200-Day Moving Average is calculated to be 0.6505.
Shares Statistics:
The stock has traded on average 617.26K shares per day over the past 3-months and 310.91k shares per day over the last 10 days, according to various share statistics. A total of 110.66M shares are outstanding, with a floating share count of 91.19M. Insiders hold about 22.80% of the company’s shares, while institutions hold 30.10% stake in the company. Shares short for FBIO as of Aug 30, 2023 were 710.9k with a Short Ratio of 0.71M, compared to 675.66k on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 0.53% and a Short% of Float of 0.72%.
Earnings Estimates
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.16 and a low estimate of -$0.25, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.17 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.79 and -$1.01 for the fiscal current year, implying an average EPS of -$0.87. EPS for the following year is -$0.43, with 3 analysts recommending between -$0.23 and -$0.75.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for FBIO’s current fiscal year. The highest revenue estimate was $65M, while the lowest revenue estimate was $53.28M, resulting in an average revenue estimate of $62.09M. In the same quarter a year ago, actual revenue was $75.74M, down -18.00% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $125.98M in the next fiscal year. The high estimate is $209.9M and the low estimate is $64.19M. The average revenue growth estimate for next year is up 102.90% from the average revenue estimate for this year.